Please login to the form below

Not currently logged in
Email:
Password:

eosinophilic

This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

NICE has published draft guidance recommending Fasenra (benralizumab), AstraZeneca’s treatment for people who have severe eosinophilic asthma. ... However, the UK's cost-effectiveness watchdog says the drug should only be used in limited circumstances

Latest news

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    The new drug has been given a green light by the EMA as an add-on maintenance treatment for severe eosinophilic asthma in patients who can’t control symptoms using ... Many patients with severe eosinophilic asthma experience debilitating symptoms and

  • GSK gets another approval for Nucala in US GSK gets another approval for Nucala in US

    The US regulator gave the go-ahead yesterday to use Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, inflammation in ... Nucala has been approved

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    The US regulator has approved the drug as an add-on treatment for severe eosinophilic asthma in patients over 12. ... The eosinophilic form is seen in about half of all severe asthma patients and is associated with worse symptoms, decreased lung function

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... The Committee for Medicinal Products for Human Use (CHMP) backed approval of benralizumab at its committee meeting

  • Sanofi, Regeneron claim EU approval for eczema drug Dupixent Sanofi, Regeneron claim EU approval for eczema drug Dupixent

    A phase III trial of the antibody in persistent, uncontrolled asthma met its targets of reducing the frequency of severe asthma attacks in patients with high levels of eosinophilic cells, setting

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 265. Meritage Pharma/ Shire. Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE).

  • Pharma deals during March 2013 Pharma deals during March 2013

    Receptos will conduct a phase II proof-of-concept study in Eosinophilic Esophagitis, an orphan indication in the US.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics